Midatech Pharma starts dosing of sustained release tumour treatment in equivalence study

04:29 EDT 21 May 2018 | Proactive Investors

Midatech wants to demonstrate that Q-Octreotide can achieve safe and effective growth hormone levels while also highlighting the advantages of its release system

More From BioPortfolio on "Midatech Pharma starts dosing of sustained release tumour treatment in equivalence study"